Hermetica Superfood Encyclopedia
The Short Answer
Anemone peptides from Actinia equina include equinins (broad-spectrum antimicrobial peptides of 2,612–3,935 Da) and equinatoxins (actinoporin pore-forming cytolysins), which disrupt bacterial and cell membranes while modulating NF-κB and Nrf-2 inflammatory pathways. In vitro data show equinin MIC values of 0.06–0.20 mg/mL against MRSA, carbapenemase-producing, and vancomycin-resistant strains, but no human clinical trials have been conducted and no standardized supplement form exists.
CategoryExtract
GroupMarine-Derived
Evidence LevelPreliminary
Primary Keywordanemone peptides Actinia equina
Anemone Peptides — botanical close-up
Health Benefits
**Broad-Spectrum Antimicrobial Activity**: Equinin A (2,612
91 Da) and Equinin B (3,934.83 Da) exhibit membrane-disrupting antimicrobial activity against Gram-positive and Gram-negative bacteria, fungi, MRSA, carbapenemase-producing strains, and vancomycin-resistant organisms, with crude fraction MICs as low as 0.125 µg/mL in vitro.
**Anti-Inflammatory Modulation**
Whole Actinia equina extracts at concentrations of 0.001–1 mg/mL inhibit IκB-α degradation and block NF-κB nuclear translocation in RAW 264.7 macrophages, suppressing pro-inflammatory cytokine cascades without measurable cytotoxicity at these concentrations.
**Antioxidant Defense Pathway Activation**: A
equina extracts activate the Nrf-2 cytoprotective pathway in macrophage cell lines, reducing oxidative stress through upregulation of antioxidant response element-driven genes; the lipid fraction contributes via EPA (C20:5 n-3) and palmitic acid (C16:0) content.
**Cytolytic and Immune Defense Properties**
Equinatoxins (actinoporins), expressed across at least five isoforms in nematocysts, tissues, and mucus, form transmembrane pores that may inform development of targeted cytolytic agents for drug delivery or antimicrobial applications.
**Potential MRSA and Drug-Resistant Pathogen Targeting**
Synthesized Equinin B demonstrates bactericidal activity against multidrug-resistant organisms at 0.25 mg/mL and a MIC of 1 mg/mL, representing a structurally novel scaffold distinct from conventional antibiotic classes.
**Rich Ancillary Lipid Bioactive Profile**: Beyond peptides, A
equina contains cholesterol (94.96% of sterols; 22,318.54 mg/kg), EPA (most abundant PUFA at 26.20% of fatty acids), and oleic acid (8.51% of MUFAs), which collectively support membrane integrity and anti-inflammatory lipid signaling in vitro.
**Investigational Anti-Infective Scaffold Development**
The structural similarity of equinins to AMPs from amphibians, fish, and other Cnidaria positions them as lead compounds for pharmaceutical development of novel anti-infective agents, particularly given rising antimicrobial resistance globally.
Origin & History
Natural habitat
Actinia equina, commonly called the beadlet anemone, is a marine cnidarian distributed throughout the Mediterranean Sea, eastern Atlantic Ocean, and Black Sea coastlines, typically inhabiting rocky intertidal zones at depths from the splash zone to approximately 20 meters. The organism anchors to hard substrates using a basal disc and deploys specialized stinging cells called nematocysts to capture prey and defend against predators. Bioactive peptides are harvested from laboratory-collected specimens via acid extraction of tentacle and body tissues, as no commercial aquaculture or standardized cultivation method currently exists.
“Actinia equina has no documented history of use in traditional medicine systems, ethnopharmacology, or as a food source in any culture, distinguishing it from many marine organisms such as sea cucumbers or certain mollusks with established culinary or folk medicinal traditions. The organism has been studied since the 19th century primarily as a model organism in marine biology for its regenerative capacity and nematocyst biology, rather than for medicinal application. Modern biomedical interest in its peptides emerged in the late 20th and early 21st centuries alongside broader discovery programs targeting marine invertebrate toxins as lead compounds for drug development, paralleling work on cone snail conotoxins and sea anemone ShK-domain peptides. All contemporary preparative and analytical work is research-driven, with no ethnobotanical, culinary, or traditional healing context recorded in the primary literature.”Traditional Medicine
Scientific Research
The current evidence base for Actinia equina peptides consists entirely of in vitro and descriptive biochemical studies, with no published human clinical trials, animal intervention studies, or randomized controlled trials identified as of 2024. Antimicrobial efficacy data derive from small-scale MIC assays against panel bacterial strains, without specification of replicate numbers, statistical power calculations, or standardized CLSI methodology reporting; crude fraction MICs ranged from 0.125 µg/mL to 0.20 mg/mL and synthesized Equinin B bactericidal concentration was 0.25 mg/mL. Anti-inflammatory and antioxidant findings originate from a single in vitro macrophage model (RAW 264.7 cells) reporting non-cytotoxicity up to 1 mg/mL and NF-κB/Nrf-2 pathway modulation, without in vivo validation or dose-response modeling in living systems. Proteomics-based identification of equinatoxin isoforms and AMP prediction studies in related anemone species provide molecular characterization but do not constitute efficacy evidence, placing the overall research at an early exploratory stage with no translational clinical data available.
Preparation & Dosage
Traditional preparation
**Acid Extract (Research Form)**
Produced by homogenizing Actinia equina tentacles and body tissue in dilute acid, centrifuging, and collecting the supernatant; no human dose established.
**HPLC-Purified Peptide Fractions**
Equinins are isolated via reverse-phase HPLC using 40% acetonitrile gradients; Equinin A and B characterized at mg/mL concentrations for in vitro assays only.
**Synthesized Equinin B (Experimental)**
25 mg/mL, MIC 1 mg/mL — no human dosing extrapolation validated
Chemically synthesized for mechanistic studies; bactericidal concentration in vitro 0..
**Whole-Organism Lipid/Sterol Extract**
001–1 mg/mL
Prepared by solvent extraction for fatty acid and sterol profiling; used in anti-inflammatory cell culture studies at 0..
**No Commercial Supplement Form Exists**
As of 2024, no standardized capsule, powder, liquid, or other consumer supplement form of A. equina peptides or extracts is commercially available or regulatory-approved for human use.
**Timing and Standardization**
No standardization percentage, bioavailability data, or clinically validated dosing interval has been established for any preparation.
Nutritional Profile
Actinia equina whole-organism extracts contain a distinctive lipid fraction comprising 50.54% saturated fatty acids (dominated by palmitic acid C16:0 and stearic acid C18:0), 23.26% monounsaturated fatty acids (with oleic acid C18:1 n-9 at 8.51%), and 26.20% polyunsaturated fatty acids (with EPA C20:5 n-3 as the most abundant single PUFA). Sterol content is dominated by cholesterol at 94.96% of total sterols, quantified at approximately 22,318.54 mg/kg of extract. Peptide content includes equinins at sub-milligram per gram tissue levels (exact quantification not reported) and equinatoxin isoforms concentrated in nematocysts; AMP-class peptides in related anemone species have been estimated at approximately 5% of the expressed proteome. Bioavailability of any oral peptide fraction is expected to be minimal without formulation protection, as gastric proteases would likely degrade equinins and equinatoxins prior to systemic absorption — no bioavailability studies have been conducted.
How It Works
Mechanism of Action
Equinins exert antimicrobial effects primarily through cationic membrane disruption: their amphipathic structural motifs intercalate into the phospholipid bilayers of bacterial membranes, inducing pore formation or membrane lysis analogous to defensins and magainins described in vertebrate systems. Equinatoxins function as actinoporins, binding sphingomyelin-rich membrane domains and oligomerizing to form toroidal transmembrane pores of approximately 2 nm diameter, causing osmotic lysis of targeted cells—a mechanism of interest for both toxicology and targeted drug delivery research. At the signaling level, A. equina whole extracts inhibit the NF-κB pathway by preventing phosphorylation-dependent IκB-α degradation, thereby blocking p65/p50 nuclear translocation and downstream transcription of TNF-α, IL-1β, and IL-6 in lipopolysaccharide-stimulated macrophages. Concurrently, Nrf-2 pathway activation by these extracts upregulates heme oxygenase-1 and other antioxidant response element genes, conferring cytoprotective effects against reactive oxygen species at non-cytotoxic concentrations (0.001–1 mg/mL in RAW 264.7 cells).
Clinical Evidence
No clinical trials in human subjects have been conducted for Actinia equina peptides or extracts in any therapeutic or nutritional context, and therefore no clinical effect sizes, confidence intervals, or outcomes data are available. The preclinical data showing in vitro antimicrobial activity (equinin MICs 0.06–0.20 mg/mL) and NF-κB suppression in macrophage models represent hypothesis-generating findings only, insufficient to support therapeutic or supplemental claims. One research group has proposed A. equina whole extract as a candidate 'new food supplement' based on its combined antioxidant, anti-inflammatory, and fatty acid profile, but this designation is speculative and unsupported by safety or efficacy studies in humans. Confidence in clinical benefit is very low; all reported outcomes require validation in animal models and subsequently in human trials before any clinical application could be considered.
Safety & Interactions
In vitro cytotoxicity testing demonstrates that A. equina extracts are non-toxic to RAW 264.7 macrophages at concentrations of 0.001–1 mg/mL, but this finding cannot be extrapolated to human in vivo safety without pharmacokinetic, acute toxicity, and repeat-dose studies. Equinatoxins are established hemolytic and pore-forming cytolysins capable of lysing erythrocytes and other mammalian cells at relevant concentrations; their behavior upon oral ingestion, dermal contact, or parenteral administration in humans is not characterized in the published literature. No drug interaction studies exist; however, the cytolytic mechanism of equinatoxins raises theoretical concern for interference with cell membrane-stabilizing drugs, and the anti-inflammatory NF-κB inhibitory activity could theoretically potentiate immunosuppressive agents. Pregnancy, lactation, and pediatric safety data are entirely absent; given the cytolytic potential of constituent toxins and complete absence of human safety data, A. equina peptide preparations must be considered investigational and are not recommended for human consumption outside controlled research settings.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Actinia equinabeadlet anemone peptidesequininsequinatoxinssea anemone antimicrobial peptidesactinoporins
Frequently Asked Questions
What are equinins and what do they do?
Equinins are novel antimicrobial peptides isolated from the tentacles and body of the beadlet sea anemone Actinia equina, with molecular masses of approximately 2,613 Da (Equinin A) and 3,935 Da (Equinin B). They disrupt bacterial cell membranes and have demonstrated in vitro activity against Gram-positive and Gram-negative bacteria, including MRSA and vancomycin-resistant strains, with crude fraction MIC values as low as 0.125 µg/mL. Currently, equinins exist only as research compounds and are not available in any commercial supplement or pharmaceutical product.
Are Actinia equina supplements safe for humans?
No human safety data exists for Actinia equina peptides or extracts, and no regulatory body has approved any A. equina preparation as a supplement or therapeutic agent. While in vitro testing shows the extract is non-cytotoxic to macrophages up to 1 mg/mL, the organism also produces equinatoxins — cytolytic pore-forming toxins that can lyse mammalian cells and red blood cells. Until human pharmacokinetic and toxicology studies are completed, A. equina preparations should be considered investigational only and are not recommended for self-administration.
What is the difference between equinins and equinatoxins?
Equinins are smaller cationic antimicrobial peptides (2,613–3,935 Da) that act by disrupting microbial membranes and are being investigated for antibiotic-resistant infection treatment. Equinatoxins are larger actinoporin proteins that function as pore-forming cytolysins, binding sphingomyelin-rich membranes and oligomerizing to create transmembrane pores, causing cell lysis — a mechanism used by the anemone for prey capture and defense. Both are produced by Actinia equina but serve distinct biological roles and carry different potential applications and risk profiles in biomedical research.
Has Actinia equina been tested in clinical trials?
As of 2024, no human clinical trials have been conducted for any Actinia equina peptide or extract preparation in any medical or nutritional context. Available evidence is restricted to in vitro cell culture studies (primarily RAW 264.7 macrophages) and biochemical characterization of isolated peptides; no animal intervention trials have been published either. The ingredient is at an early preclinical discovery stage, and significant research including safety pharmacology, in vivo efficacy, and eventually human trials would be required before any clinical application could be validated.
What conditions might anemone peptides from Actinia equina potentially help with?
Based solely on in vitro preclinical evidence, A. equina peptides show potential relevance to antimicrobial-resistant infections (equinins active against MRSA, carbapenemase-producing, and vancomycin-resistant strains), inflammatory conditions (NF-κB and Nrf-2 pathway modulation by whole extracts), and oxidative stress-related diseases (antioxidant effects attributed to EPA content and Nrf-2 activation). These are mechanistic hypotheses derived from laboratory studies and do not constitute evidence of therapeutic efficacy in humans. Significant further research is required before any health claim for specific conditions could be substantiated.
How do anemone peptides from Actinia equina compare to conventional antibiotics like vancomycin?
Anemone peptides, particularly equinins A and B, demonstrate antimicrobial activity against antibiotic-resistant organisms including vancomycin-resistant bacteria and carbapenemase-producing strains that conventional antibiotics often cannot effectively treat. Unlike vancomycin which targets cell wall synthesis, equinins disrupt bacterial membranes directly, potentially offering a distinct mechanism that may reduce resistance development. However, equinins are currently studied as research compounds rather than approved pharmaceutical replacements for conventional antibiotics.
What is the bioavailability of anemone peptides when taken orally versus other administration methods?
Most research on Actinia equina peptides has focused on direct antimicrobial activity in vitro, with limited data on oral bioavailability in humans. Peptides generally face challenges with gastrointestinal degradation and absorption, though some peptide-based supplements employ stabilization technologies to improve uptake. The specific bioavailability of equinins A and B through oral supplementation has not been thoroughly characterized in clinical studies.
Are anemone peptides from Actinia equina suitable for people with shellfish or marine allergies?
Since Actinia equina is a sea anemone (marine organism), individuals with shellfish or seafood allergies should exercise caution, as cross-reactivity to marine-derived proteins is possible. Allergic responses to marine peptides can range from mild to severe, depending on individual sensitivity and the degree of protein processing in the supplement. Anyone with documented shellfish allergies should consult a healthcare provider before using anemone peptide supplements.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w anemone-peptides-actinia-equina curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
